Back to search results

Bone-Lead Levels and Brain Health Study

This study is looking at how past lead exposure, measured in your bones, might affect brain and mental health. Researchers are using an X-Ray Fluorescence Analyzer to measure lead levels in bones. They want to see if lead exposure is linked to more severe mental illness or how well people respond to treatments like transcranial magnetic stimulation (TMS), transcranial direct-current stimulation (tDCS), electroencephalogram (EEG), and transcutaneous auricular vagus nerve stimulation (taVNS). You can join if you are 18-70 years old, can read and write English, and are already participating in certain hospital studies for neuropsychiatric disorders. The study aims to enroll 500 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information without giving new treatments. It plans to include 500 participants.
What's involved
Information will be obtained from patients, including bone-lead testing, brief cognitive tests, and self-reported psychiatric symptoms and behaviors. The duration of participation is not specified.
Compensation
Not stated in the trial record.
Follow-up
Neuropsychiatric Diagnoses and Cognitive Function are measured at Baseline. Follow-up after this is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05887934

Bone-Lead Level Associations With Brain and Mental Health

Enrolling by Invitation
Not specifiedAges 18–70Observational
Medical University of South Carolina
~500 participants
Updated 2025-10-14 on ClinicalTrials.gov
What's tested:X-Ray Fluorescence Analyzer

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Neuropsychiatric Diagnoses
Measured over Baseline
+1 more outcome measured

Conditions

Lead Exposure

Explore related trials

Alcohol use disorderAnxiety DisorderExposure to leadMood DisorderPostpartum DepressionPsychosisSchizophrenia

NCT05887934

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Medical University of South Carolina

    Charleston, South Carolinano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Dean Kilpatrick, Ph.D. · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-70
Ability to read, write, and comprehend English
Capacity to consent
Consented for recontact, when applicable
Negative pregnancy test

Exclusion

Pregnant
Current schizophrenia or psychotic disorder
Inability or unwillingness of subject to give informed consent

What this trial measures

  • Neuropsychiatric DiagnosesBaseline

    Count of participants varying neuropsychiatric disorders assessed by the Diagnostic Interview for Anxiety, Mood, and OCD and related Neuropsychiatric Disorders (DIAMOND)

  • Cognitive FunctionBaseline

    Measurement of cognitive function as assessed by the Trail Making Test (TMT) as a way to assess central executive functioning.